Adaptimmune Therapeutics (ADAP) Tops Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ADAP Hot Sheet
Join SI Premium – FREE
Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of $0.00, $0.19 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $47.6 million versus the consensus estimate of $4.9 million.
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verisk Analytics (VRSK) Tops Q3 EPS by 3c; Offers Guidance
- Lantheus Holdings (LNTH) Tops Q3 EPS by 42c
- Tripadvisor shares tumble 18% on earnings miss, CEO exit
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
